What was the outcome of the head-to-head trial between Novo Nordisk's CagriSema and Eli Lilly's tirzepatide?

The trial showed that Novo Nordisk's CagriSema was less effective than Eli Lilly's tirzepatide in reducing body weight, failing to meet the study's primary goal.

How much weight did CagriSema and tirzepatide reduce in the trial?

CagriSema achieved a 23% reduction in body weight over 84 weeks, while Eli Lilly's tirzepatide achieved a 25.5% reduction over the same period.

How did Novo Nordisk's stock perform after the trial results were announced?

Novo Nordisk's share price fell by 11% following the announcement of the trial results on Monday.

Home / Business and Economy / Novo Nordisk Obesity Drug Fails Head-to-Head Trial

Novo Nordisk Obesity Drug Fails Head-to-Head Trial

23 Feb

•

Summary

Novo's CagriSema showed less weight loss than Eli Lilly's tirzepatide.
The trial aimed to prove CagriSema was as effective as tirzepatide.
Novo Nordisk shares dropped 11% following the trial results announcement.

In a pivotal head-to-head trial, Novo Nordisk's experimental obesity drug, CagriSema, did not meet its efficacy goals when compared to Eli Lilly's tirzepatide. The study, which concluded as of Monday, February 23rd, 2026, aimed to demonstrate that CagriSema was at least as effective in weight reduction as tirzepatide. However, the results revealed CagriSema achieved a 23% body weight reduction over 84 weeks, falling short of tirzepatide's 25.5% reduction.

This outcome is a considerable blow to Novo Nordisk's efforts to lead the lucrative obesity treatment market. The company's stock experienced an 11% decline by 1002 GMT following the announcement. Despite this setback, Novo Nordisk indicated that further trials are investigating CagriSema's full potential, including higher-dose combinations. Meanwhile, Eli Lilly's shares saw a 4% increase in premarket trading.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.

Novo Nordisk Obesity Drug Fails Head-to-Head Trial

23 Feb

•

Summary

Novo's CagriSema showed less weight loss than Eli Lilly's tirzepatide.
The trial aimed to prove CagriSema was as effective as tirzepatide.
Novo Nordisk shares dropped 11% following the trial results announcement.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.